Yanis Boumber, MD, PhD
Fox Chase Cancer Center
333 Cottman Ave
Philadelphia, PA 19111
Video: Yanis Boumber, MD, PhD
Thoracic Medical Oncology, including lung cancer, thymoma and mesothelioma
Board Certified, Medical Oncology, 2013
ABIM-Internal Medicine, 2011
ECFMG Certification, 2007
After completion of my Hematology / Oncology fellowship at MD Anderson Cancer Center in 2013, I joined the medical staff at Fox Chase. I chose Fox Chase due to its excellent reputation in both high quality patient care and innovative cancer research.
Fascination with biology research and rapid advances in cancer medicine has brought me to the field of medical oncology. I love my work as a physician, enjoy taking care of cancer patients and their families, and have a great interest in lung cancer. Each patient is unique, and it is of great importance to develop individualized treatment plans designed to target specific tumors.
Fox Chase offered me a unique opportunity to work both in the clinic and in the lab. I am interested in studying basic research, as well as in translating laboratory discoveries using novel targeted agents in lung cancer to the clinic by conducting clinical trials, and above all to deliver the best possible patient care.
PhD, Cancer Biology and Molecular Biology, University of Texas M.D. Anderson Cancer Center and Graduate School of Biomedical Sciences, Houston, TX, 2005;
MD, Rostov State Medical University, Rostov-on-Don, Russia, 1999
Good Samaritan Hospital, affiliated with Johns Hopkins University, Baltimore, MD, 2007-2010
Fellowship in Hematology/Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX, 2010-2013;
Postdoctoral Fellowship, Department of Leukemia, University of Texas M.D. Anderson Cancer Center, Houston, TX, 2005-2007
Honors and Awards
Celgene Future Leaders in Hematology Award, 2012
ASCO Young Investigator Award, 2012
American Society of Hematology Merit Award, 2011
Good Samaritan Hospital, Baltimore, MD, Outstanding Performance in Ambulatory Medicine Award, 2010
Professional SocietiesAmerican Society of Hematology
American Society of Clinical Oncology
American Association of Cancer Research
Oncogenes, lung cancer, epigenetics, targeted therapy. My current research projects include 1) the role of Musashi-2 in tumor progression in NSCLC and 2) development of novel therapeutic combinations in NSCLC. Thoracic Division and Developmental Therapeutics Research Program / Assistant Professor, Clinical Investigator and Research.
Kuang SQ, Fang Z, Zweidler-McKay PA, Yang H, Wei Y, Gonzalez-Cervantes EA, Boumber Y, Garcia-Manero G. Epigenetic Inactivation of Notch-hes Pathway in Human B-cell Acute Lymphoblastic Leukemia. PLoS One 26;8(4):e61807, April 2013
Boumber Y, Kantarjian H, Jorgensen J, Faderl S, Castoro R, Autry J, Garcia-Manero G, Borthakur G, Jabbour E, Estrov Z, Cortes J, Issa JP, Ravandi F. Final Report of a Randomized Study of Decitabine Versus Conventional Care for Maintenance Therapy in Patients with Intermediate and High Risk Acute Myeloid Leukemia in First or Subsequent Complete Remission. Leukemia; 26 (11):2428-31, November 2012
Konishi K, Watanabe Y, Shen L, Guo Y, Castoro RJ, Kondo K, Chung W, Ahmed S, Jelinek J, Boumber YA, Estecio MR, Maegawa S, Kondo Y, Itoh F, Imawari M, Hamilton SR, Issa JP. DNA Methylation Profiles of Primary Colorectal Carcinoma and Matched Liver Metastasis. PLoS One; 6(11):e27889, 2011
Boumber Y, Younes A, Garcia-Manero G. Mocetinostat (MGCD0103): A Review of an Isotype-Specific Histone Deacetylase Inhibitor. Expert Opinion in Investigational Drugs;20(6):823-9, June 2011
Boumber Y and Issa, JP. Epigenetics- What’s the Future? Oncology;25(3):220-6, 228, March 2011
Si J, Boumber YA, Shu J, Qin T, Ahmed S, He R, Jelinek J, Issa JP. Chromatin Remodeling is Required for Gene Reactivation After 5-aza-2’-deoxycytidine Mediated DNA Hypomethylation. Cancer Research,1;70(17):6968-77, Sept. 2010
Kondo Y, Shen L, Cheng AS, Ahmed S, Boumber Y, Charo C, Yamochi T, Urano T, Furukawa K, Kwabi-Addo B, Gold DL, Sekido Y, Huang TH, Issa JP. Gene Silencing in Cancer by Histone H3 lysine 27 Tri-methylation Independent of Promoter DNA Methylation. Nature Genetics,40(6):741-50, June 2008.
Kondo Y, Shen L, Ahmed S, Boumber Y, Sekido Y, Haddad BR, Issa JP. Downregulation of Histone H3 lysine 9 Methyltransferase G9a Induces Centrosome Disruption and Chromosome Instability in Cancer Cells. PLoS ONE.30;3(4):e2037, April 2008
Boumber YA, Kondo Y, Chen X, Shen L, Guo Y, Tellez C, Estécio MR, Ahmed S, Issa JP. An Sp1/Sp3 binding polymorphism confers methylation protection. PLoS Genetics, 22;4(8):e1000162, Aug. 2008
Shen L, Kondo Y, Ahmed S, Boumber Y, Konishi K, Guo Y, Chen X, Vilaythong JN, Issa JP. Drug Sensitivity Prediction by CpG Island Methylation Profile in the NCI-60 Cancer Cell Line Panel. Cancer Research 1;67(23):11335-43, Dec. 2007
Boumber YA, Kondo Y, Chen X, Shen L, Gharibyan V, Konishi K, Estey E, Kantarjian H, Garcia-Manero G and Issa JP. RIL, A LIM Gene on 5q31, is Silenced by Methylation in Cancer and Sensitizes Cancer Cells to Apoptosis; Cancer Research; 67 (5):1997-2005, March 2007.